Progress and challenges in childhood tuberculosis

Lancet Infect Dis. 2013 Apr;13(4):287-9. doi: 10.1016/S1473-3099(13)70031-8. Epub 2013 Mar 24.

Authors

Ben J Marais¹, Stephen M Graham, Markus Maeurer, Alimuddin Zumla

Affiliation

¹ Sydney Emerging Infections and Biosecurity Institute, and The Children's Hospital at Westmead, University of Sydney, Locked Bag 4001, Sydney, NSW 2145, Australia. ben.marais@health.nsw.gov.au

PMID: 23531386
DOI: 10.1016/S1473-3099(13)70031-8

No abstract available

MeSH terms

AIDS-Related Opportunistic Infections* / microbiology
Adolescent
Antitubercular Agents / therapeutic use
BCG Vaccine / administration & dosage*
Child
Child, Preschool
Disease Susceptibility
Humans
Immunity, Innate
Isoniazid / therapeutic use
Mycobacterium tuberculosis* / immunology
Mycobacterium tuberculosis* / isolation & purification
Rifampin / therapeutic use
Risk Factors
Tuberculosis Vaccines / administration & dosage
Tuberculosis* / diagnosis
Tuberculosis* / drug therapy
Tuberculosis* / epidemiology
Tuberculosis* / immunology
Tuberculosis* / prevention & control
Tuberculosis, Multidrug-Resistant / diagnosis
Tuberculosis, Multidrug-Resistant / drug therapy
Tuberculosis, Multidrug-Resistant / epidemiology

Substances

Antitubercular Agents
BCG Vaccine
Tuberculosis Vaccines
Isoniazid
Rifampin